Résumé
The in-vitro activity of RP 59500 and comparative agents was determined against 270 clinical isolates of the genus Staphylococcus. MICs were performed by micro-dilution dilution. MIC90 and MBG90 (mg/L) of RP 59500 were as follows: oxacillin-sensitive Staphylococcus aureus (0.5/0.5), oxacillin-resistant S. aureus (0.5/0.5), oxacillin-sensitive Staphylococcus epidermidis (0.5/0.5), oxacillin-resistant S. epidermidis (0.25/0.25), oxacillin-resistant Staphylococcus hominis (1.0/1.0), oxacillin-resistant Staphylococcus haemolyticus (1.0/1.0), oxacillin-sensitive Staphylococcus saprophyticus (1.0/1.0). Killing kinetic methods were used to assess the bactericidal activity of inhibitory (1 –, 2 – MIC) concentrations of RP 59500 in comparison with that of vancomycin (1 – 2 – MIC) and oxacillin (1 –, 2 – MIC) against 20 strains of oxacillin-sensitive and -resistant S. aureus and S. epidermidis. RP 59500 was as active as vancomycin, displaying rapid bactericidal activity against the majority of strains tested and reducing initial inoculum counts by >99.9% in 2-12 h. Regrowth was seen with some S. epidermidis strains after 12-24 h.
| Langue d'origine | English |
|---|---|
| Pages (de-à) | 59-65 |
| Nombre de pages | 7 |
| Journal | Journal of Antimicrobial Chemotherapy |
| Volume | 30 |
| DOI | |
| Statut de publication | Published - 1992 |
| Publié à l'externe | Oui |
Note bibliographique
Funding Information:This study was supported by a grant from Rhone-Poulenc Rorcr, Princeton, New Jersey. G. G. Zhancl was sponsored by a Postdoctoral Fellowship from the Medical Research Council of Canada and Pharmaceutical Manufacturers Association of Canada—Health Research Foundation. The expert secretarial assistance of Mary Wegrzyn is appreciated.
ASJC Scopus Subject Areas
- Pharmacology
- Microbiology (medical)
- Infectious Diseases
- Pharmacology (medical)
ODD de l’ONU
Cette action contribue à la réalisation des objectifs de développement durable suivants
